Salter Malcolm
Known title: DirectorCIK: 0001825124
Associated companies
Transaction History
| CCCC | ▲ Buy | Grant | 428 | $14K | 1/4/2022 | View on chart |
| CCCC | ▼ Sell | Open Market | 755 | $23K | 12/17/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 755 | $30K | 11/19/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 755 | $34K | 10/15/2021 | View on chart |
| CCCC | ▲ Buy | Grant | 300 | $13K | 10/4/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 755 | $38K | 9/17/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 755 | $31K | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.